Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $53.45 USD
Change Today 0.00 / 0.00%
Volume 0.0
TKPHF On Other Exchanges
As of 8:10 PM 03/25/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (TKPHF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $54.62
52 Week Low
12/30/14 - $41.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

takeda pharmaceutical co ltd (TKPHF) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (TKPHF) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥216.0M
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: ¥387.0M
Managing Director of Special Missions and Dir...
Total Annual Compensation: ¥93.0M
Chief Medical & Scientific Officer and Direct...
Total Annual Compensation: ¥332.0M
Compensation as of Fiscal Year 2014.

takeda pharmaceutical co ltd (TKPHF) Key Developments

Takeda and ImmunoGen Partner to Develop Anti-Cancer Therapeutics

Takeda Pharmaceutical Company, through its wholly owned subsidiary Millennium Pharmaceuticals, has signed an agreement with ImmunoGen to develop and commercialise anti-cancer therapeutics up to two undisclosed targets. As part of the deal, Takeda has secured exclusive rights to use ImmunoGen's antibody-drug conjugate (ADC) technology, including its new DNA-acting IGN payload agents to develop targeted anti-cancer therapeutics. Takeda oncology drug discovery unit head Dr. Christopher Claiborne said: "ADC technology is a critically important tool in addressing unmet needs in oncology. Under the deal, ImmunoGen will receive $20 million upfront payment and is also eligible to receive milestone payments up to $210 million for each target, in addition to royalties on the commercial net sales of any resulting ADC products. Takeda will take responsibility for the development, manufacturing and marketing of any ADC products resulting from the deal. The deal will also allow Takeda to have a licence for a third target for an additional upfront fee.

Takeda Pharmaceutical Transfers License Agreement for HPV Vaccine to Kaketsuken

Takeda Pharmaceutical has transferred its license agreement with the Japan Health Sciences Foundation for worldwide patent rights of a human papillomavirus (HPV) vaccine (HPV vaccine) to the Chemo-Sero-Therapeutic Research Institute (Kaketsuken). After transfer of the license agreement, Kaketsuken will continue research efforts to support future commercialization of the HPV vaccine.

Takeda Pharmaceutical Company Limited and Otsuka Pharmaceutical Company, Limited Unveil Takecab in Japan

Takeda Pharmaceutical Company Limited and Otsuka Pharmaceutical Company, Limited have announced the availability of Takecab 10mg and Takecab 20mg, or Vonoprazan fumarate, in Japan. TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan fumarate has fast-acting, strong and sustained acid secretion inhibitory effects. Takeda and Otsuka executed an agreement at the end of March 2014 to co-promote TAKECAB in Japan.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPHF:US $53.45 USD 0.00

TKPHF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $68.55 USD +0.53
Becton Dickinson and Co $144.59 USD +1.38
Eli Lilly & Co $73.58 USD +0.14
Merck KGaA €103.30 EUR +0.69
Mylan NV $61.63 USD -0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation TKPHF Industry Range
Price/Earnings 64.2x
Price/Sales 2.8x
Price/Book 1.9x
Price/Cash Flow 14.1x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at